Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyPremera Bluecross Pharmacotherapy Coverage Update …
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    ModifiedPremera BluecrossPolicy 5.01.550

    Pharmacotherapy of Arthropathies

    Customize your policy alerts

    Sign up for Premera Bluecross Policy 5.01.550 alerts

    Get alerted when Policy 5.01.550 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage and prior authorization-related content for pharmacologic treatments used to manage arthropathies for Premera Bluecross members. It is intended for providers seeking policy guidance on medication coverage and relationships to other Premera pharmacotherapy policies.

    Policy Summary
    PayerPremera Bluecross
    PolicyPharmacotherapy of Arthropathies
    Policy CodePolicy 5.01.550
    Change TypeMultiple material coverage and coding updates
    Effective DateAug 1, 2026
    Last ReviewAug 1, 2026
    Next Review DateJan 1, 2026
    Key ActionVerify member plan booklet/ID to confirm whether policy 5.01.550 or policy 5.01.647 applies before submitting prior authorization requests.
    SourceLink
    POLICY UPDATE CHANGES

    Added coverage criteria for Kevzara (sarilumab) for the treatment of adult individuals with polymyalgia rheumatica (PMR).

    Updated multiple adalimumab biosimilar preferred/non-preferred designations and step therapy requirements (including moving products between preferred and non-preferred lists and adding age requirements).

    Added coverage criteria for Kevzara for certain individuals with polyarticular juvenile idiopathic arthritis (PJIA) and updated Kevzara PJIA weight requirement to at least 63 kg.

    Re-authorization duration of approval changed from 3 years to 12 months for listed agents.

    Added site-of-service reviews and exceptions for certain IV products and CRS treatment; clarified site-of-service medical necessity does not apply to Alaska fully-insured members pursuant to Alaska HB 226.

    Added coverage criteria for multiple newer agents and indications including Bimzelx (psoriatic arthritis, nr-axSpA, AS), Rinvoq LQ (PJIA, PsA), Tyenne (tocilizumab-aazg), Avtozma (tocilizumab-anoh), and others.

    Removed the note that medical necessity criteria does not apply to one Open formulary (Formulary ID: 6062; Rx Plan F1) for Enbrel (etanercept) and Simponi Aria (golimumab) IV.

    Updated Simponi Aria (golimumab) IV PJIA criterion to allow initiation concurrently with leflunomide, methotrexate, or sulfasalazine.

    Updated Kevzara (sarilumab) coverage criteria for polyarticular juvenile idiopathic arthritis (PJIA) to specify individual weights at least 63 kg.

    Reviewed prescribing information for all drugs listed in the policy (2026 update).

    Clarified that site of service applies to Simponi Aria which is the IV dosage form.

    Changed re-authorization duration from 3 years to 12 months.

    Added coverage criteria and HCPCS/NDC coding for multiple biosimilars and new products (examples: Amjevita, Tofidence, Tyenne, Avtozma, Bimzelx, Tofidence added to J3590, new HCPCS codes Q5132, Q5133, Q5156).

    Updated age requirements for many products (adalimumab products, infliximab products, Taltz, Rinvoq, Xeljanz, Cimzia, Simponi, Cosentyx, Bimzelx, Actemra, Kevzara, Orencia, Kineret, Olumiant, Stelara, Tremfya, Skyrizi, Otezla).

    Clarified that Site of Service Medical Necessity criteria does not apply to Alaska fully-insured members; only Medical Necessity criteria for the infusion drug applies pursuant to Alaska HB 226.

    Removed coverage criteria for Yuflyma (adalimumab-aaty) as product has been discontinued.

    Updated Cyltezo (adalimumab-adbm) from a preferred product to a non-preferred product.

    Updated adalimumab-aaty (Yuflyma unbranded) and Yuflyma (adalimumab-aaty) from a non-preferred product to a preferred product.

    Updated Avsola (infliximab-axxq) from a non-preferred product to a preferred product.

    Updated infliximab (Janssen - unbranded) and Remicade (infliximab) to require that the individual has had an inadequate response or intolerance to the preferred products for new starts.

    Added coverage criteria for Avtozma (tocilizumab-anoh) IV/SC and added HCPCS code Q5156.

    Removed reference to Preferred formulary (Formulary ID: 6064; Rx Plan G3) as it is no longer available.

    Updated Enbrel (etanercept) and Simponi Aria (golimumab) IV removing a prior note about applicability to a specific custom Open formulary and updated Simponi Aria (golimumab) PJIA criteria to allow concurrent start with leflunomide, methotrexate, or sulfasalazine.

    Updated Kevzara (sarilumab) coverage criteria for PJIA to require the individual weighs at least 63 kg.

    Updated age requirement for Cosentyx (secukinumab) in ankylosing spondylitis from 18 to 12 years or older.

    Updated preferred alternatives for multiple agents (including second-line adalimumab products, Cimzia, Bimzelx, Cosentyx, Actemra, Avtozma, Tofidence, Tyenne, Kevzara, Orencia, Kineret, Olumiant, Simponi SC) to include specific adalimumab products with NDCs starting with 00597.

    Updated Olumiant (baricitinib) quantity limit to 30 tablets per 30 days.

    Added tofacitinib and tofacitinib extended-release to the policy with the same criteria as Xeljanz products and added them as preferred alternatives where Xeljanz products appeared.

    Added HCPCS codes Q5137, Q5138, Q9996, Q9997, Q9998 and Q9999 missing from table.

    >10related policies referenced
    Aug 1, 2026policy effective date
    Jul 27, 2026last revision
    12 more-authorization duration
    HB 226Alaska site-of-service exception

    Coverage and Medical Necessity Criteria

    Site-of-Service Medical Necessity

    Site-of-service medical necessity rules apply to medical benefit reviews; review of site applies to individuals aged 13 and older except Alaska fully‑insured members.

    Site-of-Service Application: Apply site-of-service review for intravenous (IV) and injectable drug administration under the medical benefit for individuals aged 13 years or older.age >=13

    SOS Medical Necessity applies to medical benefit reviews; age threshold and Alaska exception noted

    Alaska exception: Site-of-service medical necessity criteria does NOT apply to Alaska fully-insured members; for those members use the infusion and injection drug medical necessity criteria only; contact Customer Service for questions.

    Alaska fully-insured exception per Alaska HB 226

    Medically necessary sites:
    Policy Summary
    PayerPremera Bluecross
    PolicyPharmacotherapy of Arthropathies
    Policy CodePolicy 5.01.550
    Change TypeMultiple material coverage and coding updates
    Effective DateAug 1, 2026
    Last ReviewAug 1, 2026
    Next Review DateJan 1, 2026
    Key ActionVerify member plan booklet/ID to confirm whether policy 5.01.550 or policy 5.01.647 applies before submitting prior authorization requests.
    SourceLink
    On This Page
    Coverage and Medical Necessity CriteriaBilling Codes, HCPCS, and Quantity/ThresholdsPrior Authorization, Documentation, and Denial RisksClinical and Policy BackgroundTerms and Thresholds
    Physician's office, home infusion, hospital-based outpatient, and outpatient hospital IV infusion department are considered medically necessary sites of service when criteria are met.

    Preferred medically necessary sites listed

    Hospital-based outpatient special rules: Hospital-based outpatient setting is considered medically necessary for the first 90 days for the initial course of infusion or for re-initiation after >=6 months, when no outpatient infusion center within 50 miles or no contracted home infusion agency will travel, or when the individual has clinical conditions that increase infusion risk (e.g., symptomatic cardiac or significant pulmonary disease, unstable renal function, difficult vascular access, acute cognitive impairment, prior severe drug reactions/anaphylaxis).first 90 days; re-initiation after >=6 months

    Criteria and high-risk conditions specified

    Not medically necessary sites: Sites that do not meet the policy's site-of-service criteria are considered not medically necessary for infusion/injectable therapy services.

    Claims billed for IV drugs must be processed through the medical benefit; noncompliant sites considered not medically necessary

    Ankylosing Spondylitis — Drug-specific Criteria

    Agent-specific medical necessity criteria for ankylosing spondylitis in adults (age ≥18) — prescriber specialty and prior‑therapy requirements vary by agent.

    Age requirement: Individual is aged 18 years or older.>=18 years

    Applies to most ankylosing spondylitis agent criteria

    Prescriber: Medication must be prescribed by or in consultation with a rheumatologist.

    Rheumatologist involvement required for listed agents

    First-line TNF-α inhibitors: Certain TNF-α antagonists (examples include adalimumab products starting with specified NDCs, etanercept, infliximab products, others listed) may be considered medically necessary as first-line when age and prescriber requirements are met; specific product rules and site-of-service review (for some IV infliximab/Simponi Aria IV) apply.

    See agent-specific entries for site-of-service and NDC specifications

    Agents requiring prior inadequate response: Some agents (e.g., Cimzia, Simponi SC, certain infliximab products, others) require documented inadequate response or intolerance to specified prior drugs (agent-specific lists and number of prior agents vary) before being considered medically necessary.

    Agent-specific prior trial counts described in policy

    Second-line IL-17 example: Bimzelx (bimekizumab-bkzx) may be considered medically necessary for ankylosing spondylitis when age ≥18 AND inadequate response or intolerance to one of: etanercept, specified adalimumab products (NDCs starting with 00597), or ixekizumab, AND prescribed by or in consultation with a rheumatologist.

    Example of second-line IL-17 requirement

    Ankylosing spondylitis

    Agents may be considered medically necessary for ankylosing spondylitis when ALL of the following are met:

    Age: Individual is aged 18 years or older.18 years

    Adult age requirement for ankylosing spondylitis agents

    Prior therapy: Has had an inadequate response or intolerance to the specified prior drugs per agent (examples: some agents require inadequate response to two listed drugs; others require failure of listed TNF or alternative agents).As specified per agent

    Agent-specific prior trial requirements outlined in policy

    Prescriber: Medication is being prescribed by or in consultation with a rheumatologist.

    Rheumatologist involvement requirement

    Polyarticular juvenile idiopathic arthritis (JIA)

    Coverage for polyarticular juvenile idiopathic arthritis (PJIA) varies by agent and line; examples of agent- and line-specific criteria include:

    Age: Individual is aged 2 years or older for many listed PJIA agents.>=2 years

    Age minimums for PJIA agents

    Aggressive disease: Individual has aggressive disease (per Related Information) where specified for certain agents.

    Aggressive disease required for several PJIA agents

    Prior therapy — conventional DMARDs: Has had an inadequate response or intolerance to leflunomide, methotrexate, or sulfasalazine OR is being started on biologic concurrently with one of these agents where allowed.

    DMARD trial requirement or concurrent start allowance noted

    Prescriber: Medication is being prescribed by or in consultation with a rheumatologist.

    Rheumatologist involvement required

    Agent-specific restrictions and sequencing: Some products require additional prior biologic failures, heart-failure/lymphoproliferative exceptions, or have NDC-specific preferred/non-preferred sequencing (examples: Kevzara weight requirement, adalimumab NDC trials); product-specific lists determine exact prior agents and counts.

    See product-specific PJIA criteria (e.g., Kevzara weight >=63 kg; Simponi Aria IV site-of-service review)

    Systemic juvenile idiopathic arthritis (Systemic JIA) — IL‑6 inhibitors

    IL-6 inhibitors may be considered medically necessary for systemic juvenile idiopathic arthritis when ALL of the following are met:

    Age: Individual is aged 2 years or older.>=2 years

    Age threshold for IL-6 inhibitors in SJIA

    Prior therapy: Has had an inadequate response or intolerance to a corticosteroid, leflunomide, methotrexate, or a nonsteroidal anti-inflammatory drug (NSAID).

    Prior trial requirement for IL-6 inhibitors in SJIA

    Prescriber: Medication is being prescribed by or in consultation with a rheumatologist.

    Rheumatologist involvement required

    Site-of-service review: Certain IV formulations of IL-6 inhibitors are subject to site-of-service administration review.

    IV forms subject to SOS review

    Enthesitis-related arthritis — Cosentyx (secukinumab)

    Cosentyx (secukinumab) may be considered medically necessary for enthesitis‑related arthritis when ALL of the following are met:

    Age: Individual is aged 4 years or older.>=4 years

    Age requirement for Cosentyx in enthesitis-related arthritis

    Prescriber: Medication is being prescribed by or in consultation with a rheumatologist.

    Rheumatologist involvement required

    Rheumatoid arthritis (moderate to severe)

    Rheumatoid arthritis (moderate to severe) coverage is arranged in step tiers; agents may be considered medically necessary when ALL of the following apply:

    Age: Individual is aged 18 years or older for listed RA agents.>=18 years

    Adult age requirement for RA biologic/targeted agents

    Prior therapy: Has not responded to or does not tolerate conventional DMARDs (hydroxychloroquine, leflunomide, methotrexate, or sulfasalazine) prior to many biologic/JAK agents; exact prior-agent sequencing depends on step tier and product-specific rules.

    DMARD requirement and step therapy sequencing

    Prescriber: Medication is being prescribed by or in consultation with a rheumatologist.

    Rheumatologist involvement required

    Site-of-service: Certain infliximab products, Simponi Aria IV, and other IV agents are subject to site-of-service review for administration.

    IV agents may require SOS review

    Adalimumab biosimilars — rheumatoid arthritis

    Adalimumab biosimilars for rheumatoid arthritis are covered when ALL of the following are met:

    Age and DMARD requirement: Individual is aged 18 years or older AND has not responded to or does not tolerate leflunomide, hydroxychloroquine, methotrexate, or sulfasalazine.

    Adult RA baseline DMARD requirement

    Prescriber: Medication is being prescribed by or in consultation with a rheumatologist.

    Prescriber specialty required

    Product/NDC specifics: Applies to adalimumab biosimilars such as adalimumab-aaty, adalimumab-adaz, adalimumab-adbm (NDCs starting with 00597) according to product-specific coverage lists.

    NDC-specific preferred/non-preferred sequencing applies

    IL-6 inhibitors — first-line and second-line RA coverage

    IL‑6 inhibitors for RA may be covered as first- or second-line depending on prior therapy; examples:

    IL-6 first-line: Individual is aged 18 years or older AND has had an inadequate response or intolerance to hydroxychloroquine, leflunomide, methotrexate, or sulfasalazine AND either has inadequate response to an adalimumab biosimilar (or meets specified exceptions such as heart failure/prior lymphoproliferative disorder) AND medication prescribed by or in consultation with a rheumatologist.

    First-line IL-6 examples include tocilizumab agents; IV forms subject to site-of-service review

    IL-6 second-line: Individual is aged 18 years or older AND has not responded to listed conventional agents AND has had documented trial and treatment failure with specified infliximab products (e.g., Avsola and Inflectra) AND medication prescribed by or in consultation with a rheumatologist.

    Second-line IL-6 examples and required infliximab trials

    Second-line agents (anti-CD20, IL-1, T-cell modulators, JAKs) — RA

    Second-line agents for RA (anti‑CD20, IL‑1, T‑cell modulators, JAKs) are covered when ALL listed criteria are met:

    Anti-CD20 (rituximab): Individual is aged 18 years or older AND has not responded to or does not tolerate conventional DMARDs AND meets criteria in related rituximab policy (5.01.556) AND medication prescribed by or in consultation with a rheumatologist.

    Rituximab coverage references policy 5.01.556

    IL-1 (anakinra): Individual is aged 18 years or older AND has not responded to or does not tolerate conventional DMARDs AND has had an inadequate response or intolerance to two of specified agents (e.g., select biologics, JAKs) AND medication prescribed by or in consultation with a rheumatologist.

    Kineret (anakinra) second-line IL-1 criteria

    T-cell costimulation modulators (abatacept): Individual is aged 18 years or older AND has not responded to or does not tolerate conventional DMARDs AND has had an inadequate response or intolerance to two of specified agents AND has relevant comorbidity exceptions where indicated (e.g., heart failure, prior lymphoproliferative disorder) AND medication prescribed by or in consultation with a rheumatologist.

    Orencia IV/SC; IV subject to site-of-service review

    JAK inhibitors (baricitinib and others): Individual is aged 18 years or older AND has not responded to or does not tolerate conventional DMARDs AND has had an inadequate response or intolerance to two of specified agents AND medication prescribed by or in consultation with a rheumatologist.Quantity limit: 30 tablets per 30 days for baricitinib

    Baricitinib quantity limit and cosmetic exclusion for alopecia noted

    Non-radiographic axial spondyloarthritis — agents and criteria

    Non‑radiographic axial spondyloarthritis agents and criteria — covered when ALL of the following are met:

    Age: Individual is aged 18 years or older.>=18 years

    Adult age requirement for nr-axSpA agents

    Objective signs of inflammation: Has objective signs of inflammation defined as at least one of: CRP elevated beyond the upper limit of normal for the reporting laboratory OR sacroiliitis reported on MRI.

    Objective inflammation required for several agents

    Prescriber: Medication is being prescribed by or in consultation with a rheumatologist.

    Rheumatologist involvement required

    Agent-specific sequencing: First-line options include TNF blockers (e.g., Cimzia) and IL-17 inhibitors or JAK inhibitors (e.g., Taltz, Rinvoq) with second-line IL-17 agents (Bimzelx, Cosentyx) requiring inadequate response to prior agents as specified; Cosentyx IV is subject to site-of-service review.

    Agent sequencing and site-of-service for IV Cosentyx

    Polymyalgia rheumatica (PMR) — Kevzara

    Kevzara (sarilumab) may be considered medically necessary for polymyalgia rheumatica (PMR) when ALL of the following are met:

    Age: Individual is aged 18 years or older.>=18 years

    Adult PMR population

    Prior corticosteroid trial: Has had an inadequate response to one systemic corticosteroid.

    Requirement of inadequate response to systemic corticosteroid

    Prescriber: Medication is being prescribed by or in consultation with a rheumatologist.

    Rheumatologist involvement required

    Narrative coverage considerations and clinical criteria

    Narrative coverage considerations and clinical criteria summarized from policy text:

    Site-of-service age requirement: Site-of-service medical necessity review for infusion/administration locations is limited to individuals aged 13 years and older.age >=13

    Pediatric considerations and specialty infusion training rationale

    Early DMARD initiation: Initiate DMARD therapy (or combination) within three months of RA diagnosis to reduce early joint damage; selection influenced by disease severity, predictors (e.g., CRP >=4.1 mg/dL), comorbidities, and monitoring needs.time from diagnosis <=3 months

    CRP >=4.1 mg/dL cited as predictor of rapidly progressive disease

    JIA therapy hierarchy: First-line: NSAIDs; if inadequate, DMARDs (methotrexate, sulfasalazine); TNF blockers and other immune suppressants for refractory disease; choice depends on extent of disease and prior response.

    Therapeutic approach for JIA described

    PMR diagnostic approach: PMR diagnosis supported by history, physical exam, elevated ESR/CRP, and sometimes MRI/ultrasound; trial of low-dose glucocorticoids used diagnostically with documentation of response.

    Diagnostic and therapeutic trial guidance for PMR

    Selected updated coverage criteria and rules — changelog highlights

    Selected updated coverage criteria and rules (changelog highlights):

    Kevzara additions: Kevzara (sarilumab) added for PMR (adult) and PJIA criteria updated; PJIA coverage requires individual weight at least 63 kg.weight >=63 kg for PJIA

    Additions and weight threshold reflected in updates

    Adalimumab product sequencing: Multiple adalimumab biosimilars were reclassified between preferred and non-preferred lists; non-preferred adalimumab coverage requires trial and failure of all preferred adalimumab products for new starts.

    Preferred vs non-preferred sequencing updated

    Re-authorization duration change: Re-authorization duration for approvals was changed from 3 years to 12 months for listed agents.12 months

    Re-authorization duration update

    Site-of-service and formulary exceptions: Site-of-service reviews were added or clarified for several IV products; site-of-service criteria do not apply to Alaska fully-insured members; providers must verify member plan applicability.

    Alaska HB 226 exception and plan verification noted

    Step therapy exceptions: Brand step therapy exceptions were added for certain agents when individuals have heart failure, prior treated lymphoproliferative disorder, previous serious infection, or demyelinating disorder.

    Clinical exceptions to step therapy updated

    Simponi Aria (golimumab) PJIA initiation

    Simponi Aria (golimumab) PJIA initiation update:

    Concurrent csDMARD initiation allowed: For polyarticular juvenile idiopathic arthritis, Simponi Aria (golimumab) IV may be started concurrently with leflunomide, methotrexate, or sulfasalazine per the updated criteria.

    2026 update permits concurrent initiation with specified csDMARDs

    Kevzara (sarilumab) PJIA weight-based coverage

    Kevzara (sarilumab) PJIA weight‑based coverage — requirement summary:

    Weight requirement: Individual must weigh at least 63 kg for Kevzara (sarilumab) use in polyarticular juvenile idiopathic arthritis.>= 63 kg

    Weight threshold updated in 2026; see PJIA criteria for additional requirements

    Aggressive disease and prior therapy: Kevzara PJIA coverage also requires aggressive disease and inadequate response or intolerance to leflunomide, methotrexate, or sulfasalazine and to two specified agents per product-specific sequencing.

    PJIA treatment sequencing and aggressive disease requirement

    Formulary applicability for Enbrel and Simponi Aria IV

    Formulary applicability and plan verification for Enbrel and Simponi Aria IV:

    Formulary applicability: The prior note excluding one Open formulary (Formulary ID: 6062; Rx Plan F1) from the medical necessity criteria for Enbrel and Simponi Aria IV was removed; providers must verify the member's plan booklet or ID card to determine whether this policy or policy 5.01.647 applies.

    Removed exception; check member plan to determine applicable policy

    Summary of updated coverage criteria (high-level)

    High-level summary of updated coverage criteria across multiple agents and indications:

    TNF blocker prerequisite updates: Several agents (e.g., selected JAK inhibitors and other biologics) now require an inadequate response to one or more TNF blockers for specified indications; check drug-specific criteria for exact prerequisites.

    Step therapy sequencing updated across drugs

    Age requirement updates: Age requirements were added or updated for many biologics across indications (examples include adalimumab products, infliximab products, Taltz, Rinvoq, Xeljanz, Cimzia, Cosentyx, Bimzelx, Actemra, Kevzara, Orencia, Kineret, Olumiant, Stelara, Tremfya, Skyrizi, Otezla).

    Age thresholds changed for multiple products

    Preferred vs non-preferred sequencing: Preferred biosimilar and brand product lists were updated; some non-preferred adalimumab products now require trial and failure of all preferred adalimumab products prior to coverage for new starts.

    Product preference and required trials updated

    Site-of-service reviews and exceptions: Site-of-service review was added or clarified for several IV products (examples: Simponi Aria IV, Cosentyx IV, tocilizumab IV variants); site-of-service criteria do not apply to Alaska fully-insured members and exceptions were added for individuals treated for cytokine release syndrome (CRS).

    SOS reviews and Alaska/CRS exceptions noted

    PJIA specific updates: PJIA criteria for multiple agents were updated to require aggressive disease and in some cases weight thresholds (e.g., Kevzara >=63 kg); Simponi Aria PJIA initiation may be concurrent with specified csDMARDs.

    PJIA updates summarized

    Updated Coverage Criteria (summarized)

    Selected summarized coverage updates affecting sequencing and limits:

    Infliximab new start requirement: For new starts of infliximab (Janssen unbranded) and Remicade (infliximab), the individual must have had an inadequate response or intolerance to preferred products.

    New-start requirement for infliximab/Remicade

    Preferred alternative adalimumab products: Multiple agents list specific adalimumab products (NDCs starting with 00597) as preferred alternatives which should be tried before some non-preferred products where applicable.

    Preferred adalimumab alternatives updated across indications

    Olumiant quantity limit: Olumiant (baricitinib) quantity is limited to 30 tablets per 30 days.30 tablets per 30 days

    Quantity limit updated

    This fragment functions as an index/cross-reference within the larger Pharmacotherapy of Arthropathies policy and does not itself contain full, drug-specific coverage logic. For detailed medical necessity criteria, prior authorization steps, step therapy tiers, and documentation requirements, refer to the specific drug sections in this policy and the related Premera pharmacotherapy policies listed elsewhere in the document.

    This policy references multiple related Premera pharmacotherapy policies for condition- and product-specific criteria. When seeking prior authorization or clinical criteria for a particular agent or indication, review the related policy cross-references listed (examples include 5.01.575, 5.01.607, 5.01.628, 5.01.629, 5.01.645 and 5.01.647) to confirm applicable requirements and any plan-specific exceptions.

    Site-of-service medical necessity reviews apply to medical benefit determinations for IV and injectable drugs, but do not apply to Alaska fully‑insured members; for those members apply only the infusion/injection drug medical necessity criteria. For site-of-service review, the policy applies to individuals aged 13 years or older (site-of-service reviews are limited to age ≥13).

    Members enrolled in the specified custom Open formulary that was previously exempt (Formulary ID: 6062; Rx Plan F1) are now redirected to follow policy 5.01.647 for medical necessity criteria. Providers should verify the member's plan booklet or member ID card to determine whether the custom formulary applies or whether to proceed under this policy.

    All other uses of the listed agents when administered in combination with each other or when used for conditions not specified in this policy or the related policies are considered investigational. Providers should not rely on this policy for coverage of off‑label combination therapies or indications not explicitly addressed here.

    Site-of-service review for pediatric IV insertions and infusion therapy is limited to individuals aged 13 years or older; requests for site-of-service determinations for children younger than 13 are not supported by this policy's site-of-service criteria.

    The policy states that use of Olumiant (baricitinib) for the treatment of alopecia is considered a cosmetic indication and is not covered under this policy.

    Members previously covered under the exempt custom Open formulary should now be evaluated under policy 5.01.647; providers must check member plan materials to determine which policy governs prior authorization requests for these members.

    The policy reiterates that baricitinib (Olumiant) use for alopecia is considered cosmetic and is not covered; such cosmetic use is explicitly excluded from medical necessity coverage.

    Coverage criteria for Yuflyma (adalimumab-aaty) were removed from the policy because the product has been discontinued.

    The rationale for removal of Yuflyma coverage criteria is that the product is discontinued; therefore Yuflyma-specific coverage rules have been deleted from the policy.

    This excerpt does not include explicit 'not medically necessary' statement text beyond the site-of-service and product‑specific exclusions already noted; detailed not‑medically‑necessary determinations appear elsewhere in the full policy.

    Sites that do not meet the policy's site-of-service criteria are considered not medically necessary for infusion and injectable therapy services; claims for IV-administered drugs must be processed under the medical benefit and may be denied if site‑of‑service requirements are not met.

    Use of baricitinib (Olumiant) for alopecia is explicitly identified as a cosmetic use and is therefore not covered by this policy.

    Requests for site-of-service review for patients younger than 13 years are not supported by this policy; site‑of‑service medical necessity determinations apply only to individuals aged 13 and older.

    Uses that fall outside FDA dosing/administration guidance or the policy's specific clinical criteria — including cosmetic indications and off‑label dosing or administration — are potentially not covered. Providers should document FDA‑approved dosing and indication when submitting requests.

    An investigational/not medically necessary table is included elsewhere in the full policy (referenced historically in the policy's references and changelog); this excerpt does not reproduce that table but refers providers to the main policy for full investigational and not‑medically‑necessary listings.

    Baricitinib (Olumiant) use for alopecia is categorized as cosmetic and excluded from coverage; this exclusion is stated repeatedly in the policy history and product sections.

    Billing Codes, HCPCS, and Quantity/Thresholds

    NDC prefixes referencedNDC
    NDCs starting with 00597Adalimumab products — preferred alternative adalimumab NDC prefix referenced for product-specific criteria
    NDCs starting with 82009NDC prefix referenced (documented in inventory; ensure included)
    Covered HCPCS/Codes (selected list)HCPCSCovered
    J0139Injection, abatacept (Orencia), 10 mg
    J1602Injection, golimumab (Simponi Aria), 1 mg, for intravenous use
    J1628Injection, guselkumab (Tremfya), 1 mg
    J1745Injection, infliximab, excludes biosimilar (Remicade or Janssen unbranded), 10 mg
    J3247Injection, secukinumab, intravenous (Cosentyx) 1 mg
    J3262Injection, tocilizumab (Actemra), 1 mg
    Biosimilar HCPCS/Q-codesHCPCSCovered
    Q5103Injection, infliximab-dyyb, biosimilar (Inflectra), 10 mg
    Q5104Injection, infliximab-abda, biosimilar (Renflexis), 10 mg
    Q5121Injection, infliximab-axxq, biosimilar (Avsola), 10 mg
    Q5133Injection, tocilizumab-bavi (Tofidence), biosimilar, 1 mg
    Q5135Injection, tocilizumab-aazg (Tyenne), biosimilar, 1 mg
    Q5140Injection, adalimumab-fkjp, biosimilar, 1 mg
    Q5141Injection, adalimumab-aaty, biosimilar, 1 mg
    Q5142Injection, adalimumab-ryvk, biosimilar, 1 mg
    Q5143Injection, adalimumab-adbm, biosimilar, 1 mg
    Q5144Injection, adalimumab-aacf (Idacio), biosimilar, 1 mg
    1–10 of 18
    1/2
    Rituximab biosimilar codeHCPCSCovered
    Q5115Injection, rituximab-abbs, biosimilar (Truxima), 10 mg
    Historical HCPCS and coding updates mentionedHCPCS
    J1602HCPCS code referenced in historical updates
    Q5103HCPCS code referenced in historical updates
    Q5104HCPCS code referenced in historical updates
    Q5121HCPCS code for Avsola referenced in historical updates
    HCPCS / Unclassified codes referencedHCPCS
    J3590Unclassified biologics (use to report various biologics added to J3590 list)
    Q5132New HCPCS code added (documented in references)
    Q5133New HCPCS code added (documented in references)
    Q5156New HCPCS code added (documented in references)
    J0139New HCPCS code added (documented in references)
    Q5140New HCPCS code added (documented in references)
    Q5141New HCPCS code added (documented in references)
    Q5142New HCPCS code added (documented in references)
    Q5143New HCPCS code added (documented in references)
    Q5144New HCPCS code added (documented in references)
    1–10 of 19
    1/2
    Updated HCPCS codesHCPCS
    Q5156HCPCS code added for Avtozma (tocilizumab-anoh) IV/SC
    Q5137HCPCS code added (documented as added to table)
    Q5138HCPCS code added (documented as added to table)
    Q9996HCPCS code added (documented as added to table)
    Q9997HCPCS code added (documented as added to table)
    Q9998HCPCS code added (documented as added to table)
    Q9999HCPCS code added (documented as added to table)
    Age minimums by agent/indication
    Age minimums (examples)Policy age minimums vary by agent/indication: 2 years (selected IL‑6 inhibitors, systemic JIA/PJIA), 4 years (Cosentyx for enthesitis‑related arthritis), 12 years (Cosentyx for ankylosing spondylitis — updated), and 18 years (many adult RA/AS indications)
    Source note — pediatric JIASeveral PJIA and systemic JIA agents list a minimum age of 2 years in the criteria
    Source note — enthesitis‑related arthritisCosentyx (secukinumab) criteria specify age ≥4 years
    Source note — ankylosing spondylitisAge requirement for some ankylosing spondylitis agents (Cosentyx) was updated from 18 to 12 years
    Weight threshold (Kevzara PJIA)
    Kevzara (sarilumab) PJIA weight thresholdIndividual must weigh at least 63 kg for Kevzara to be considered medically necessary for polyarticular juvenile idiopathic arthritis
    Kevzara PJIA — related requirementCoverage also requires 'aggressive disease' and prior inadequate response/intolerance to specified DMARDs per PJIA criteria
    Policy updateKevzara PJIA weight requirement was added/updated in the 2026 policy revision notes
    Objective signs of inflammation (acceptability criteria)
    Objective signs of inflammation — definitionAt least one of: C‑reactive protein (CRP) elevated beyond the upper limit of normal for the reporting laboratory OR sacroiliitis reported on magnetic resonance imaging (MRI)
    ApplicabilityRequired for therapies in non‑radiographic axial spondyloarthritis and some AS approvals (e.g., Taltz, Rinvoq, Bimzelx, Cosentyx)
    DocumentationCRP results or MRI report should be documented to demonstrate objective inflammation per policy criteria
    Quantity limit (baricitinib)
    Olumiant (baricitinib) quantity limitQuantity limited to 30 tablets per 30 days
    Indication contextLimit applies to baricitinib when used for rheumatoid arthritis indications per policy updates
    Policy noteUse of baricitinib for alopecia is considered cosmetic and not covered (separate exclusion)
    CRP threshold referenced in background
    CRP threshold referenced in backgroundCRP ≥ 4.1 mg/dL is cited as a predictive risk factor associated with rapidly progressive rheumatoid arthritis
    Clinical implicationElevated CRP (≥4.1 mg/dL) may influence selection of more aggressive DMARD therapy earlier in disease course
    Source contextReferenced in the RA background discussion as a key predictor of rapid progression
    Kevzara PJIA weight (duplicate reference)
    Kevzara (sarilumab) PJIA weight threshold (restated)>= 63 kg required for Kevzara coverage in PJIA
    Associated criteriaAlso requires aggressive disease and prior inadequate response/intolerance to specified DMARDs
    Update historyWeight threshold added/confirmed in 2026 update notes
    Re-authorization duration
    Re-authorization durationRe-authorization approvals updated to a duration of 12 months
    Prior durationPreviously re-authorization duration was 3 years (updated to 12 months in the revision notes)
    Provider actionProviders should submit re-authorization requests reflecting the 12‑month limit to avoid denial
    Kevzara weight threshold restated
    Kevzara (sarilumab) PJIA weight requirement (restated)>= 63 kg is required for Kevzara coverage in polyarticular juvenile idiopathic arthritis
    Associated PJIA criteriaRequirement accompanies other PJIA criteria such as aggressive disease and prior inadequate response to leflunomide, methotrexate, or sulfasalazine
    Policy revision noteWeight threshold was explicitly updated in the 2026 policy revision notes
    Cosentyx age threshold for ankylosing spondylitis
    Cosentyx (secukinumab) age threshold — ankylosing spondylitisCosentyx age requirement for ankylosing spondylitis updated to ≥ 12 years
    Prior agePreviously listed age requirement for some AS/axSpA agents was 18 years; Cosentyx specifically was updated to 12 years
    Prescriber requirementMedication must be prescribed by or in consultation with a rheumatologist per agent criteria
    Olumiant quantity limit
    Olumiant (baricitinib) quantity limit (restated)Quantity limited to 30 tablets per 30 days
    Context in criteriaLimit is specified in the JAK inhibitor (Olumiant) RA coverage criteria; use for alopecia is excluded as cosmetic
    Policy updateQuantity limit was added/confirmed in recent policy updates

    Prior Authorization, Documentation, and Denial Risks

    Prior Authorization

    Policy included in Premera pharmacotherapy set — PA may apply

    This policy is part of Premera's pharmacotherapy policy set and may include prior authorization requirements; the excerpt contains no explicit PA instructions or affected billing codes — providers must refer to the related policy sections when submitting authorizations.

    Prior Authorization

    See referenced policies for prior authorization details

    This excerpt does not list specific prior authorization rules; providers must consult the related policies referenced here (e.g., policies in the pharmacotherapy set) for the applicable PA criteria and submission instructions.

    Note

    Related policy index — no PA rules shown here

    This section functions as an index of related policies and does not itself contain prior authorization requirements; use the listed policy numbers/titles to find PA rules that apply to a given agent or indication.

    Prior Authorization

    Cross-reference to policy-specific prior authorization

    This excerpt cross-references other policy numbers for agent- and indication-specific prior authorization criteria; providers must consult those policy-specific pages for PA rules before requesting authorization.

    Prior Authorization

    Site-of-service medical necessity review required for select IV/injectables

    Select IV and other injectable biologics named in this policy are subject to a site-of-service medical necessity review prior to coverage; these include multiple infliximab and IV tocilizumab products and Simponi Aria IV.

    • Examples: Actemra IV, Avsola, Avtozma IV, Cosentyx IV, Inflectra, Infliximab (Janssen), Orencia IV, Remicade, Renflexis, Simponi Aria IV, Tofidence IV, Tyenne IV
    Prior Authorization

    PA requires age, prior trials, and rheumatologist documentation

    Prior authorization for listed agents often requires documentation of the patient's age, prior trials/failures or intolerance to specified therapies, and that the medication is prescribed by or in consultation with a rheumatologist; some IV agents will also trigger site-of-service review.

    • Document age and prescriber (rheumatologist) involvement
    • Document prior treatment trials, failures, or intolerances per agent
    • Anticipate site-of-service review for select IV formulations
    Prior Authorization

    Prior authorization approvals commonly granted up to 12 months

    When drug-specific criteria and documentation are met, initial authorizations (and re-authorizations) for many agents may be approved for up to 12 months; submit chart notes demonstrating continued positive clinical response for re-authorization.

    • Initial and re-authorization approvals: up to 12 months
    • Re-authorization requires chart notes showing clinical benefit
    Prior Authorization

    Site-of-service age requirement: age ≥13

    Site-of-service medical necessity review for infusion/administration applies only to individuals aged 13 years or older — pediatric site-of-service reviews are limited due to specialized infusion needs.

    • Site-of-service age threshold: ≥ 13 years
    Prior Authorization

    PA approvals aligned to 12‑month re-authorization duration

    Prior authorization approvals and re-authorization durations have been aligned to the updated 12-month re-authorization period; ensure PA requests reflect the 12‑month authorization framework.

    • Re-authorization period updated from 3 years to 12 months
    Prior Authorization

    Verify policy applicability (Enbrel/Simponi Aria Open formulary change)

    Verify applicable policy and member plan before requesting prior authorization: previous note exempting a custom Open formulary (Formulary ID: 6062; Rx Plan F1) from these criteria was removed — members with that formulary now follow policy 5.01.647.

    • Check member plan booklet or ID card to determine whether policy 5.01.550 or policy 5.01.647 applies
    Billing Rule

    Use updated HCPCS/NDC coding when requesting authorizations

    Prior authorization and authorization coding requirements were updated to include additional biosimilars and new HCPCS/Q-codes; providers must use the updated HCPCS/NDC codes (and J3590 where indicated) when submitting PA requests.

    • Updated codes include J3590 and new Q-codes (examples: Q5156 added for Avtozma)
    Prior Authorization

    PA requirements updated for added agents and biosimilars

    Prior authorization criteria and coverage lists were revised to add agents and biosimilars (e.g., additional tocilizumab products, tofacitinib additions) and to update PA rules; providers should submit PA requests per the revised product-specific criteria.

    • Policy updates reflect added agents, biosimilars, and coding; follow the current drug-specific criteria when requesting PA
    Step Therapy

    No step therapy specifics in this excerpt — refer to policy sections

    The provided excerpt does not define specific step therapy rules here; see the policy sections referenced for complete step therapy tiers and required prior agent trials.

    Step Therapy

    Step therapy tiers and disease-state prior trial requirements

    Step therapy tiers are described elsewhere in the policy; tiers include first-line TNF inhibitors followed by IL-6, IL-17, JAKs, anti-CD20, IL-1, and T-cell costimulation modulators — providers must document required prior trials/failures per disease-state tiering.

    • Disease-state tiering dictates required prior agents before later-line therapies
    • Document prior trials/failures according to the tier applicable to the indication
    Step Therapy

    Step therapy requiring trial of preferred adalimumab alternatives (NDCs 00597)

    Step therapy rules require documented trials and inadequate response/intolerance to preferred adalimumab alternatives (specific NDCs starting with 00597) before initiating certain non-preferred adalimumab products.

    • Preferred adalimumab alternatives: NDCs starting with 00597
    • New starts of some adalimumab-related agents require failure of preferred adalimumab products
    Step Therapy

    Concurrent csDMARD initiation allowed with Simponi Aria in PJIA

    Simponi Aria IV for PJIA may be initiated concurrently with a csDMARD (leflunomide, methotrexate, or sulfasalazine) per the updated PJIA initiation criteria; document concurrent csDMARD use in the PA request.

    • Concurrent initiation allowed: leflunomide, methotrexate, or sulfasalazine
    Note
    Note
    Note
    Note
    Documentation Required

    Document rheumatologist involvement and prior-treatment trials

    Providers must submit clinical documentation demonstrating prescriber specialty and prior-treatment history: many approvals require the medication be prescribed by or in consultation with a rheumatologist and include documented trials/failures of specified prior agents.

    • Document rheumatologist prescribing or consultation
    • Provide prior-treatment trial and failure history per agent-specific criteria
    Note
    Documentation Required

    Required clinical documentation (office notes, diagnostics, prior response)

    Submit office visit notes that include diagnosis, relevant history, physical exam, and medication history; for PMR, document history, exam, inflammatory markers (ESR/CRP), imaging if applicable, and response to a low‑dose glucocorticoid trial.

    • Office visit notes with diagnosis, history, exam, medication history
    • For PMR: ESR/CRP, MRI/ultrasound as applicable, and glucocorticoid trial response
    Note
    Documentation Required

    Verify member plan/formulary before PA (Open formulary now follows policy 5.01.647)

    Verify the member's plan booklet or member ID card before submitting authorizations: the prior open-formulary exception was removed and members with the custom Open formulary (Formulary ID: 6062; Rx Plan F1) now follow policy 5.01.647.

    • Check member plan booklet/ID to determine whether policy 5.01.550 or policy 5.01.647 applies
    Note
    Billing Rule

    Non‑formulary exception approvals may be up to 12 months — verify plan

    Non-formulary exception approvals for drugs in this policy may be granted for up to 12 months; confirm plan applicability and document clinical justification when requesting non‑formulary exceptions.

    • Non-formulary exception duration: up to 12 months
    • Check member plan booklet/ID for custom formulary applicability
    Documentation Required

    Document prior response/intolerance to preferred products for new starts

    Document prior use and inadequate response or intolerance to preferred products when initiating certain non-preferred agents (for example, new starts of infliximab or Remicade require documented inadequate response/intolerance to preferred products).

    • For new starts of infliximab (Janssen unbranded) and Remicade: document inadequate response/intolerance to preferred products
    Billing Rule

    IV-administered drugs billed to medical benefit — site‑of‑service denials possible

    Claims for IV‑administered drugs must be processed under the medical benefit (not pharmacy); failure to meet site‑of‑service medical necessity criteria for an IV administration site may result in claim denial.

    • IV-administered drugs → bill via medical benefit
    • Site-of-service criteria not met → service considered not medically necessary and may be denied
    Denial Risk

    Formulary applicability check — removed exception may cause denial

    If a provider relies on a previously-removed formulary exception (Open formulary ID: 6062; Rx Plan F1) coverage may be denied — verify which policy governs the member (policy 5.01.550 vs. 5.01.647) before submitting requests.

    Denial Risk

    Denial risk if medical necessity or documentation requirements are not met

    Failure to meet product-specific medical necessity criteria or to provide required documentation of prior trials, age/weight thresholds, or continued clinical response may result in denial or reduced authorization.

    • Missing required prior trials or intolerance documentation
    • Not meeting age or weight thresholds (e.g., Kevzara PJIA weight ≥63 kg)
    • Insufficient chart notes showing ongoing clinical benefit for re-authorization
    Prior Authorization

    Re-authorization duration updated to 12 months — reflect in requests

    Re-authorization duration for approvals was changed from 3 years to 12 months; ensure re-authorization requests reflect the 12‑month limit to avoid denial for exceeding allowable authorization length.

    • Re-authorization duration: 12 months (updated from 3 years)
    Prior Authorization

    Infliximab/Remicade new‑start prior therapy requirement — document failures

    New starts of infliximab (Janssen unbranded) and Remicade require documentation of inadequate response or intolerance to preferred products; failure to document this prior therapy requirement may trigger denial.

    • Document inadequate response/intolerance to preferred infliximab alternatives before initiating infliximab (Janssen) or Remicade
    Note
    Note
    Note

    Clinical and Policy Background

    Related policy listings and the site-of-service index are presented in this fragment as references rather than full criteria; consult the referenced policy sections for operational prior authorization steps and denials guidance.

    Policy cross-reference index
    Policy cross-reference indexMultiple related Premera pharmacotherapy policies are listed for reference (examples: 5.01.575, 5.01.607, 5.01.628, 5.01.629, 5.01.645, 5.01.647)
    Provider actionProviders should consult related policies (listed) for indication-specific prior authorization and clinical criteria
    Volume~20 related policy cross-references appear in the document fragments

    The policy references a separate investigational/not medically necessary table elsewhere in the full document; this fragment notes that such a table exists and that detailed NMN determinations are captured in other sections.

    Terms and Thresholds

    Definitions
    Definitions(Definitions section placeholder - content not present in this fragment)
    ActionRefer to full policy for complete definitions list
    NoteThis block is a header placeholder in the source extract
    Site of service — definition summary
    Site of service — definitionThe location where the drug is administered (e.g., hospital-based outpatient setting, infusion center, physician's office, or at home)
    Site-of-service age ruleSite-of-service medical necessity review is limited to individuals aged 13 years or older
    RelevanceCertain IV agents are subject to site-of-service administration review per policy
    Enthesitis-related arthritis — definition
    Enthesitis-related arthritis — definitionA category of juvenile idiopathic arthritis that includes children with arthritis and enthesitis (inflammation at tendon, ligament, or joint capsule insertion sites)
    Agent exampleCosentyx (secukinumab) is listed for enthesitis-related arthritis with age ≥4 years
    Clinical noteDiagnosis involves identification of enthesitis in pediatric patients
    Site of service — location examples and relevance
    Site of service — location examplesHospital outpatient, infusion center, physician's office, or at home
    Why it mattersSite determines medical necessity review and may affect coverage processing (medical benefit claims for IV-administered drugs)
    Pediatric considerationPediatric IV administration requires specialty infusion training; age threshold for site review is ≥13 years
    Site of service — hospital outpatient, infusion center, office, home
    Common site examplesHospital outpatient, infusion center, physician office, home infusion
    Policy effectCertain IV products (e.g., some tocilizumab formulations, Cosentyx IV, infliximab IV products) are subject to site-of-service review
    Claims processingIV-administered drugs must be billed to the medical benefit; site-of-service criteria not met may render service not medically necessary
    PJIA aggressive disease — definition and risk factors
    PJIA — aggressive disease (definition summary)PJIA that may be progressive, particularly in children <10 years; factors such as rheumatoid factor positivity, HLA-DR4, or anti-CCP antibodies increase risk for aggressive course
    Policy use'Aggressive disease' is required qualifier for PJIA coverage for certain agents
    Clinical implicationPresence of aggressive disease influences eligibility for biologic therapies per policy criteria
    Low disease activity / remission threshold
    Low disease activity/remission thresholdDAS28-CRP <2.6
    ContextUsed as a measure of low disease activity or remission in rheumatoid arthritis trials cited in policy summaries
    Clinical endpointReferenced in Kevzara trial results as measure of disease activity
    Primary efficacy endpoint (ACR20 at week 24)
    Primary efficacy endpoint — RA trialsACR20 response at week 24
    Use in trialsPrimary endpoint used in Kevzara and other RA drug trials described in policy background
    InterpretationACR20 used to assess response to treatment in moderate to severe RA studies
    PJIA abbreviation note
    PJIA abbreviationPJIA = Polyarticular Juvenile Idiopathic Arthritis
    UsageAbbreviation used throughout the policy for juvenile polyarticular JIA indications
    Related itemsUsed in Kevzara and Simponi Aria PJIA criteria sections
    Site of Service Medical Necessity criteria — summary
    Site of Service Medical Necessity criteria — summaryPolicy-level review determining whether infusion/injection administration site meets medical necessity; exceptions exist for Alaska fully-insured members and for CRS treatment
    Action for providersVerify site-of-service applicability and member plan (Alaska exception) before requesting medical benefit coverage for IV/injectable drugs
    ImplicationFailure to meet site-of-service criteria may result in denial or reprocessing under pharmacy benefit
    Aggressive disease (PJIA) — definition context
    Aggressive disease (PJIA) — policy contextRequired qualifier for coverage of several PJIA agents (e.g., tocilizumab products, adalimumab products, Kevzara) and may trigger step therapy exceptions
    When to applyAssess aggressive disease features (RF positivity, HLA-DR4, anti-CCP) when evaluating PJIA biologic eligibility
    Policy changesMultiple PJIA criteria updated in recent reviews to include aggressive disease requirement
    Preferred alternative adalimumab products — definition list reference
    Preferred alternative adalimumab products — summaryPreferred alternatives include specific adalimumab products (NDCs starting with 00597) listed as first-line options before certain non-preferred agents
    Policy effectNon-preferred adalimumab products require trial and inadequate response to all preferred adalimumab products for new starts
    ExamplesPreferred alternatives updated across multiple indications including PJIA, RA, AS
    New start requirement for infliximab agents
    New start requirement for infliximab agents — summaryNew starts of infliximab (Janssen unbranded) and Remicade require documented inadequate response or intolerance to preferred products
    Coding/authorization impactApplies to prior authorization and may require documentation of trials with preferred infliximab alternatives or adalimumab products
    Policy updateRequirement added in 2025-2026 interim reviews